Medicus Pharma Ltd reports results for the quarter ended June 30 - Earnings Summary
Medicus Pharma Ltd reports results for the quarter ended June 30 - Earnings Summary
Medicus Pharma Ltd MDCX.OQ reported a quarterly adjusted loss of 21 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of four analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -15 cents to -11 cents per share.
Reported revenue was zero; analysts expected zero.
Medicus Pharma Ltd's reported EPS for the quarter was a loss of 21 cents.
The company reported a quarterly loss of $11.68 million.
Medicus Pharma Ltd shares had fallen by 22.5% this quarter and lost 77.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 28.2% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Medicus Pharma Ltd is $4.00, about 91.7% above its last closing price of $0.33
This summary was machine generated from LSEG data August 12 at 10:34 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.13 | -0.21 | Missed |
Mar. 31 2026 | -0.19 | -0.31 | Missed |
Dec. 31 2025 | -0.15 | -0.83 | Missed |
Sep. 30 2025 | -0.29 | -0.65 | Missed |
Recent news on Medicus Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer